Correlation Between Morgan Stanley and BioCryst Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Morgan Stanley and BioCryst Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Morgan Stanley and BioCryst Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Morgan Stanley Direct and BioCryst Pharmaceuticals, you can compare the effects of market volatilities on Morgan Stanley and BioCryst Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Morgan Stanley with a short position of BioCryst Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Morgan Stanley and BioCryst Pharmaceuticals.

Diversification Opportunities for Morgan Stanley and BioCryst Pharmaceuticals

-0.27

Correlation Coefficient

Morgan Stanley  BioCryst Pharmaceuticals

Very good diversification

The 3 months correlation between Morgan and BioCryst is -0.27. Overlapping area represents the amount of risk that can be diversified away by holding Morgan Stanley Direct and BioCryst Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on BioCryst Pharmaceuticals and Morgan Stanley is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Morgan Stanley Direct are associated (or correlated) with BioCryst Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of BioCryst Pharmaceuticals has no effect on the direction of Morgan Stanley i.e., Morgan Stanley and BioCryst Pharmaceuticals go up and down completely randomly.

Pair Corralation between Morgan Stanley and BioCryst Pharmaceuticals

Given the investment horizon of 90 days Morgan Stanley Direct is expected to generate 0.3 times more return on investment than BioCryst Pharmaceuticals. However, Morgan Stanley Direct is 3.3 times less risky than BioCryst Pharmaceuticals. It trades about 0.11 of its potential returns per unit of risk. BioCryst Pharmaceuticals is currently generating about 0.0 per unit of risk. If you would invest  1,954  in Morgan Stanley Direct on September 22, 2024 and sell it today you would earn a total of  130.00  from holding Morgan Stanley Direct or generate 6.65% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Morgan Stanley Direct  vs.  BioCryst Pharmaceuticals

Morgan Stanley Direct

Risk-Adjusted Performance

8 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Morgan Stanley Direct are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite quite unfluctuating fundamental indicators, Morgan Stanley may actually be approaching a critical reversion point that can send shares even higher in January 2025.

BioCryst Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days BioCryst Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, BioCryst Pharmaceuticals is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Morgan Stanley and BioCryst Pharmaceuticals

The main advantage of trading using opposite Morgan Stanley and BioCryst Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Morgan Stanley position performs unexpectedly, BioCryst Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioCryst Pharmaceuticals will offset losses from the drop in BioCryst Pharmaceuticals' long position.

The idea behind Morgan Stanley Direct and BioCryst Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.